ANTIBODY REAGENT KITS
Waiver type - Procurement: Nonavailability
Agency: NATIONAL INSTITUTES OF HEALTH (7529) • Product Service Code (PSC) : 6505 | Last Modified: 12/23/2024
Procurement Summary
• In accordance with FAR Subpart 8.002(a)(1) Priorities for Use of Government Supply Sources, research conducted revealed that none of the mandatory Government sources could satisfy this requirement. o This type of product/service in not offered from internal inventory of our agency or other agencies, not offered by Federal Prison Industries, it is not on the Ability One Procurement Lists, nor on any wholesale supply sources. • GSA Library Search was conducted, and the items are not available. • ACQUISITION ALERT 2023-12: Mandatory Consideration of Designated Agency Contracts: Contracting Officers shall first consider sourcing from the list of HHS Mandatory Consideration Contract Vehicles for any in-scope goods or services meeting the needs of the requestor before acquiring from other sources. These agency contracts have been reviewed and the required supplies are not available on these contracts. • The NIH BPA commodities list was also reviewed, specifically the vendors and agreements listed in the Biological Materials section. Although this list provided some insight into vendors who may be able to provide the instrument to NIH, the Maximum Order Limit (MOL) is $25,000. The item is not available on a BPA. • Existing contract mechanism were also surveyed to avoid any duplication of efforts as to ensure efficient acquisition strategies. For example, the NIH wide contracting vehicles list in the Office of Acquisitions, Office of Logistics and Acquisition Operations (OLAO), was considered. This list included NITAAC, for IT commodities, NIHCATS for conference administration and Beckman Coulter for equipment maintenance. None of the NIH wide contracts support this requirement. • Open Market Research: A Google search under “Antibody Purification Kits,” “Antibody Purification Kits manufactured in the United States.” No domestic antibodies that met the requirements for the end-user were identified.
Waiver Rationale Summary
Based on the findings detailed above, the antibodies are not mined, produced, or manufactured in the United States in sufficient and reasonably available commercial quantities and of a satisfactory quality. Therefore, it is hereby determined, consistent with FAR 25.103(b)(2), that these items are not available.
Yes
Yes
Consistent with Policy
DRUGS AND BIOLOGICALS
325414 - Biological Product (except Diagnostic) Manufacturing
12/18/2024
N/A
Pre-solicitation
0 - 6 months
Individual Waiver
NATIONAL INSTITUTES OF HEALTH